Aridis Pharmaceuticals, Inc.
DelistedCIK 1614067fmd_1PYWQRN4DFA826SGCSX67MX9T8Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2023, 26 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Total revenues | 1 | 3 | 1 | 1 | 2 | 3 |
| Research and development | 17 | 23 | 24 | 17 | 37 | 26 |
| Operating income | (20) | (24) | (29) | (22) | (43) | (30) |
| Interest and investment income | 0 | 0 | 0 | – | – | – |
| Net income | (25) | (22) | (30) | (22) | (42) | (30) |
| Net income to common shareholders | (27) | (23) | (30) | (22) | (46) | (30) |